Use of a calcium sulfate-calcium phosphate synthetic bone graft composite in the surgical management of primary bone tumors

Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical s...

Full description

Saved in:
Bibliographic Details
Published in:Orthopedics (Thorofare, N.J.) Vol. 36; no. 2; pp. e216 - e222
Main Authors: Evaniew, Nathan, Tan, Victoria, Parasu, Naveen, Jurriaans, Erik, Finlay, Karen, Deheshi, Benjamin, Ghert, Michelle
Format: Journal Article
Language:English
Published: United States SLACK INCORPORATED 01-02-2013
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate-calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate-calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm(3). Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm(3). Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate-calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate-calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors.
AbstractList Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate-calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate-calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm(3). Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm(3). Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate-calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate-calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors.
Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate-calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate-calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm super(3). Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm super(3). Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate-calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate-calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors.
Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate--calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate--calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm3 . Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm3 . Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate--calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate--calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors.
Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate–calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate–calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm 3 . Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm 3 . Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate–calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate–calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors.
Author Finlay, Karen
Jurriaans, Erik
Evaniew, Nathan
Deheshi, Benjamin
Ghert, Michelle
Tan, Victoria
Parasu, Naveen
Author_xml – sequence: 1
  givenname: Nathan
  surname: Evaniew
  fullname: Evaniew, Nathan
  organization: Department of Surgery, Division of Orthopaedics, McMaster University, Hamilton, Ontario, Canada
– sequence: 2
  givenname: Victoria
  surname: Tan
  fullname: Tan, Victoria
– sequence: 3
  givenname: Naveen
  surname: Parasu
  fullname: Parasu, Naveen
– sequence: 4
  givenname: Erik
  surname: Jurriaans
  fullname: Jurriaans, Erik
– sequence: 5
  givenname: Karen
  surname: Finlay
  fullname: Finlay, Karen
– sequence: 6
  givenname: Benjamin
  surname: Deheshi
  fullname: Deheshi, Benjamin
– sequence: 7
  givenname: Michelle
  surname: Ghert
  fullname: Ghert, Michelle
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23380017$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1v3CAQhlG0UbL5-AdRhNRLLm6YAQx7rKJ8VIrUS3O2MAu7jmzjgn1Y9c8HZ3dz6KUnNMzzvgPzXpBFH3pHyA2w73yF-p6BUEoIVSADzgCxQHlClrDiukBeqgVZzkgxM-fkIqV3xhhXoM_IOXKuGQO1JH_fkqPBU0OtaW0zdTRNrTejK471sA1p2OYbmnb9uHVjY2mdn0I30fiR2tANITW53fQ0t7M-bpospp3pzcZ1rh_nAUNsOhN3e-k4dSGmK3LqTZvc9eG8JG9Pj78fXorXX88_H368FpaXeiwQLDfo0Rmja7mWiKiErb2HUjMwALY0pgbhkUm-ltKupBTGOiuULWu_5pfkbu87xPBncmmsuiZZ17amd2FKFfDsqUFJ_X8UtSgRQWFGv_2Dvocp9vkjnxTTACgzJfaUjSGl6Hx1WEQFrJpzrI45Vsccq0_Z7cF8qju3_hIdg-MfNZ2a-Q
CODEN ORTHDK
CitedBy_id crossref_primary_10_1542_pir_2015_0128
crossref_primary_10_1002_jbm_b_34132
crossref_primary_10_3390_bioengineering10020208
crossref_primary_10_1007_s10856_017_6017_1
crossref_primary_10_1089_ten_teb_2018_0381
crossref_primary_10_1007_s00256_015_2189_2
crossref_primary_10_1016_j_rboe_2017_04_003
crossref_primary_10_1016_j_bea_2023_100107
crossref_primary_10_1016_j_proeng_2014_09_048
crossref_primary_10_3928_01477447_20181023_03
crossref_primary_10_1186_s12891_017_1623_0
crossref_primary_10_3390_antibiotics11070969
crossref_primary_10_2106_JBJS_M_01332
crossref_primary_10_1016_j_carj_2014_11_004
crossref_primary_10_3390_nano13152219
crossref_primary_10_1002_jor_24046
crossref_primary_10_1002_jbm_b_34700
crossref_primary_10_3390_polym14030547
crossref_primary_10_1186_s12891_015_0828_3
crossref_primary_10_3390_ma15030827
crossref_primary_10_3390_ijms23147590
crossref_primary_10_3390_ani14101460
crossref_primary_10_1177_0885328219849712
crossref_primary_10_7547_17_020
crossref_primary_10_1177_11207000231212423
crossref_primary_10_5005_jp_journals_10024_3337
crossref_primary_10_1177_2041731418776819
crossref_primary_10_1002_jbm_b_34318
crossref_primary_10_1002_jor_24508
crossref_primary_10_7759_cureus_20002
crossref_primary_10_1016_j_clineuro_2016_12_011
crossref_primary_10_1177_10225536241254200
crossref_primary_10_1007_s10856_014_5344_8
crossref_primary_10_1016_j_injury_2021_11_057
crossref_primary_10_1097_BPO_0000000000001680
crossref_primary_10_5371_hp_2021_33_3_167
crossref_primary_10_1016_j_tcr_2021_100405
crossref_primary_10_1098_rsos_191830
crossref_primary_10_1111_os_12509
crossref_primary_10_1021_acsabm_8b00221
crossref_primary_10_1016_j_cden_2019_12_006
crossref_primary_10_1007_s10561_016_9582_5
crossref_primary_10_1016_j_msec_2020_111032
crossref_primary_10_3390_molecules26103007
crossref_primary_10_1016_j_jmbbm_2015_07_027
crossref_primary_10_1039_D4TB00262H
crossref_primary_10_1038_s41598_017_02048_w
crossref_primary_10_1007_s10856_017_5940_5
crossref_primary_10_1586_14737140_2014_901891
crossref_primary_10_3390_jfb12040056
crossref_primary_10_1016_j_rbo_2016_07_014
crossref_primary_10_5397_cise_2022_00969
crossref_primary_10_1007_s00270_023_03390_5
crossref_primary_10_1177_1947603518770249
crossref_primary_10_1016_j_ceramint_2014_03_059
crossref_primary_10_1021_acsbiomaterials_3c00399
Cites_doi 10.1097/01.blo.0000160024.06739.ff
10.1007/s11999-012-2251-5
10.1097/00005131-200203000-00001
10.1097/00003086-199603000-00011
10.1002/jbm.10268
10.1007/s00256-010-1037-7
10.1097/01.blo.0000150371.77314.52
10.1016/j.ocl.2005.08.005
10.1007/s00264-006-0156-1
10.3928/01477447-20080801-31
10.4103/0019-5413.39588
10.1097/BLO.0b013e318059b902
10.1563/1548-1336-35.1.28
10.1007/s00432-008-0427-x
10.2106/00004623-199412000-00009
10.3928/0147-7447-20010201-19
10.2106/00004623-199906000-00008
10.3928/0147-7447-20040102-11
10.1177/230949901001800111
10.5435/00124635-201009000-00009
10.1097/01.blo.0000174684.85250.b5
10.1016/0030-4220(64)90372-X
10.1111/j.1708-8208.2009.00221.x
10.2174/1874325000802010091
10.1177/230949900801600116
10.2106/00004623-199311000-00009
10.1097/00003086-200204000-00029
ContentType Journal Article
Copyright Copyright 2013, SLACK Incorporated.
Copyright 2013, SLACK Incorporated
Copyright_xml – notice: Copyright 2013, SLACK Incorporated.
– notice: Copyright 2013, SLACK Incorporated
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7RV
7X7
7XB
88E
88I
8AF
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB0
M0S
M1P
M2P
NAPCQ
PQEST
PQQKQ
PQUKI
PRINS
Q9U
S0X
7X8
7QP
DOI 10.3928/01477447-20130122-25
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Science Database
Nursing & Allied Health Premium
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
SIRS Editorial
MEDLINE - Academic
Calcium & Calcified Tissue Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Central Student
ProQuest Central Essentials
SIRS Editorial
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
Calcium & Calcified Tissue Abstracts
DatabaseTitleList MEDLINE
Calcium & Calcified Tissue Abstracts
ProQuest Central Student
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1938-2367
EndPage e222
ExternalDocumentID 2882851941
10_3928_01477447_20130122_25
23380017
Genre Journal Article
GroupedDBID ---
.GJ
04C
0R~
123
29N
29O
36B
3V.
4.4
53G
5RE
6PF
7RV
7X7
88E
88I
8AF
8AO
8FI
8FJ
AAQQT
AAWTL
ABJNI
ABPPZ
ABUWG
ACGFS
ACGOD
ADBBV
ADFRT
ADOJX
AENEX
AFKRA
AHMBA
AKWKQ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BENPR
BKEYQ
BMSDO
BPHCQ
BVXVI
C45
CCPQU
CGR
CUY
CVF
DU5
DWQXO
EBD
EBS
ECM
ECT
EIF
EIHBH
EJD
EMB
EMOBN
EX3
F5P
FYUFA
GNUQQ
HCIFZ
HMCUK
HZ~
IAO
IHR
INH
IPT
ITC
M1P
M2P
M2Q
N4W
NAPCQ
NPM
O9-
OVD
PCD
PQQKQ
PROAC
PSQYO
RWG
RWL
S0X
SJN
SV3
TAE
TEORI
UKHRP
WH7
WOW
XFW
YCJ
ZCN
ZGI
ZXP
AAYXX
CITATION
7XB
8FK
K9.
PQEST
PQUKI
PRINS
Q9U
7X8
7QP
ID FETCH-LOGICAL-c368t-21c3a2f2eaa8b5d522274cbff16801a11c6aab14f2053d55c9554acec47c6bfd3
ISSN 0147-7447
IngestDate Fri Oct 25 05:48:06 EDT 2024
Sat Oct 05 04:39:48 EDT 2024
Thu Oct 10 15:59:27 EDT 2024
Thu Nov 21 21:56:51 EST 2024
Sat Sep 28 07:53:10 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Copyright 2013, SLACK Incorporated.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c368t-21c3a2f2eaa8b5d522274cbff16801a11c6aab14f2053d55c9554acec47c6bfd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 23380017
PQID 1284081125
PQPubID 40235
PageCount 1
ParticipantIDs proquest_miscellaneous_1352281758
proquest_miscellaneous_1284622172
proquest_journals_1284081125
crossref_primary_10_3928_01477447_20130122_25
pubmed_primary_23380017
PublicationCentury 2000
PublicationDate 2013-Feb
2013-02-00
20130201
PublicationDateYYYYMMDD 2013-02-01
PublicationDate_xml – month: 02
  year: 2013
  text: 2013-Feb
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Thorofare
PublicationTitle Orthopedics (Thorofare, N.J.)
PublicationTitleAlternate Orthopedics
PublicationYear 2013
Publisher SLACK INCORPORATED
Publisher_xml – name: SLACK INCORPORATED
References Kelly CM (e_1_3_1_21_2) 2004; 27
e_1_3_1_22_2
e_1_3_1_23_2
e_1_3_1_24_2
e_1_3_1_8_2
e_1_3_1_7_2
e_1_3_1_9_2
e_1_3_1_20_2
e_1_3_1_4_2
e_1_3_1_29_2
e_1_3_1_3_2
McCanless J (e_1_3_1_18_2) 2009; 33
e_1_3_1_6_2
Campanacci M (e_1_3_1_5_2) 1990; 75
e_1_3_1_25_2
e_1_3_1_26_2
e_1_3_1_2_2
e_1_3_1_27_2
e_1_3_1_28_2
e_1_3_1_13_2
e_1_3_1_12_2
e_1_3_1_11_2
e_1_3_1_30_2
e_1_3_1_10_2
e_1_3_1_17_2
e_1_3_1_16_2
e_1_3_1_15_2
e_1_3_1_14_2
e_1_3_1_19_2
References_xml – ident: e_1_3_1_4_2
  doi: 10.1097/01.blo.0000160024.06739.ff
– ident: e_1_3_1_22_2
  doi: 10.1007/s11999-012-2251-5
– ident: e_1_3_1_17_2
  doi: 10.1097/00005131-200203000-00001
– ident: e_1_3_1_6_2
  doi: 10.1097/00003086-199603000-00011
– ident: e_1_3_1_16_2
  doi: 10.1002/jbm.10268
– ident: e_1_3_1_14_2
  doi: 10.1007/s00256-010-1037-7
– volume: 75
  start-page: 212
  issue: 1
  year: 1990
  ident: e_1_3_1_5_2
  article-title: Curettage of giant cell tumor of bone. reconstruction with subchondral grafts and cement
  publication-title: Chir Organi Mov
  contributor:
    fullname: Campanacci M
– volume: 33
  start-page: 99
  year: 2009
  ident: e_1_3_1_18_2
  article-title: Comparison of bone graft substitutes through protein adsorption and cellular response
  publication-title: Trans Orthop Res Soc
  contributor:
    fullname: McCanless J
– ident: e_1_3_1_8_2
  doi: 10.1097/01.blo.0000150371.77314.52
– ident: e_1_3_1_23_2
  doi: 10.1016/j.ocl.2005.08.005
– ident: e_1_3_1_27_2
  doi: 10.1007/s00264-006-0156-1
– ident: e_1_3_1_30_2
  doi: 10.3928/01477447-20080801-31
– ident: e_1_3_1_29_2
  doi: 10.4103/0019-5413.39588
– ident: e_1_3_1_12_2
  doi: 10.1097/BLO.0b013e318059b902
– ident: e_1_3_1_13_2
  doi: 10.1563/1548-1336-35.1.28
– ident: e_1_3_1_19_2
  doi: 10.1007/s00432-008-0427-x
– ident: e_1_3_1_20_2
  doi: 10.2106/00004623-199412000-00009
– ident: e_1_3_1_26_2
  doi: 10.3928/0147-7447-20010201-19
– ident: e_1_3_1_2_2
  doi: 10.2106/00004623-199906000-00008
– volume: 27
  start-page: s131
  issue: 1
  year: 2004
  ident: e_1_3_1_21_2
  article-title: Treatment of benign bone lesions with an injectable calcium sulfate-based bone graft substitute
  publication-title: Orthopedics
  doi: 10.3928/0147-7447-20040102-11
  contributor:
    fullname: Kelly CM
– ident: e_1_3_1_24_2
  doi: 10.1177/230949901001800111
– ident: e_1_3_1_11_2
  doi: 10.5435/00124635-201009000-00009
– ident: e_1_3_1_7_2
  doi: 10.1097/01.blo.0000174684.85250.b5
– ident: e_1_3_1_15_2
  doi: 10.1016/0030-4220(64)90372-X
– ident: e_1_3_1_25_2
  doi: 10.1111/j.1708-8208.2009.00221.x
– ident: e_1_3_1_9_2
  doi: 10.2174/1874325000802010091
– ident: e_1_3_1_28_2
  doi: 10.1177/230949900801600116
– ident: e_1_3_1_3_2
  doi: 10.2106/00004623-199311000-00009
– ident: e_1_3_1_10_2
  doi: 10.1097/00003086-200204000-00029
SSID ssj0003718
Score 2.2895668
Snippet Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage e216
SubjectTerms Activities of daily living
Adolescent
Adult
Bone Neoplasms - surgery
Bone Substitutes
Bone Transplantation
Calcium Phosphates
Calcium Sulfate
Curettage
Cysts
Disease transmission
Ethics
Female
Humans
Male
Middle Aged
Morbidity
Patients
Reconstructive Surgical Procedures
Retrospective Studies
Tumors
Young Adult
Title Use of a calcium sulfate-calcium phosphate synthetic bone graft composite in the surgical management of primary bone tumors
URI https://www.ncbi.nlm.nih.gov/pubmed/23380017
https://www.proquest.com/docview/1284081125
https://search.proquest.com/docview/1284622172
https://search.proquest.com/docview/1352281758
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELa6y4ULAvEqLMhI3FAWYjtpekTQ1apadZE2RXuLHMehFWpT5cGFP8-M7TjZFaDlwCVKncSJPF_H34xnxoS8FQmYJkKyQMzyKBBznQeyyD8ExSzKYxWBWWSKuJ5fzVbXyeeFWEwm_aYlQ9t_lTS0gawxc_YfpO07hQY4B5nDEaQOxzvJfW2d8_IdDL7adjuMPy-BUAb978Omag4baMFqBUD_sGJrXgHX_FbLsjUx5hjIpfsIyKarrXbc-UgZEybtylSYR9tuV7llIUd0L-t2Ux1wFci4ddNNBQpfWof36nR5OvJAIJk3FW1R16Mnf_AmGJX4dYsLC1s_f3yRtWw6e_sPPaSyLdGbKZ1hAPr9-9ijgbtL-OgQbbXwHLQwlpYbq2lbJ8XBkY10rmZhPJq_NbOJzrfnBiCCLt8BGC-Wp8A12xBMcZt4fbMU9-oyO1tfXGTp4jo9IvcYaDFUolfLlZ_mOczqNhcTe37_u35vcp0_GDCGyKQPyQNngdCPFjqPyETvH5OfABtalVRSBxN6CzbUw4Z62FCUPTWwoR42dLuncJn2sKEDbPAFDjb2UQubJ2R9tkg_nQduX45A8ThpAxYqLlnJtJRJHhURplMLlZdlGAPfkWGoYinzUJQMNHwRRWoOnFUqrcRMxXlZ8KfkeA9veU4o5wJ9DCoBO1cUhZAxU1qoGOz4hPNyPiVBP4KZ-8AMzFYc8awf8awf8YxFU3LSD3Pm_pRNhhQMmG-Il9_4y6BGcW1M7nXV2Xtihru1_eUeNFYS4NvJlDyzIvQfxThPkPG9uMMbXpL7A-xPyHFbd_oVOWqK7rWB2C89eacr
link.rule.ids 315,782,786,27933,27934
linkProvider Multiple Vendors
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+a+calcium+sulfate-calcium+phosphate+synthetic+bone+graft+composite+in+the+surgical+management+of+primary+bone+tumors&rft.jtitle=Orthopedics+%28Thorofare%2C+N.J.%29&rft.au=Evaniew%2C+Nathan&rft.au=Tan%2C+Victoria&rft.au=Parasu%2C+Naveen&rft.au=Jurriaans%2C+Erik&rft.date=2013-02-01&rft.eissn=1938-2367&rft.volume=36&rft.issue=2&rft.spage=e216&rft.epage=e222&rft_id=info:doi/10.3928%2F01477447-20130122-25&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0147-7447&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0147-7447&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0147-7447&client=summon